Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIORNASDAQ:EVAXNYSE:PTNNASDAQ:SCNI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIORBiora Therapeutics$0.14-0.4%$0.14$0.15▼$7.90$611K1.1269,927 shs1,496 shsEVAXEvaxion Biotech A/S$2.36+25.5%$1.58$1.20▼$20.81$3.31M-0.24606,854 shs584,520 shsPTNPalatin Technologies$0.09-44.6%$0.00$0.09▼$2.48$2.45M0.942.28 million shs14.57 million shsSCNIScinai Immunotherapeutics$2.82+2.3%$2.64$1.90▼$8.92$2.82M2.23279,603 shs517 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIORBiora Therapeutics0.00%0.00%+3.85%-20.59%-97.73%EVAXEvaxion Biotech A/S0.00%+9.95%+13.94%-13.36%-90.69%PTNPalatin Technologies0.00%0.00%-54.54%+9,409,900.00%+9,409,900.00%SCNIScinai Immunotherapeutics0.00%-2.48%+9.56%-17.66%-33.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIORBiora Therapeutics1.7884 of 5 stars3.50.00.00.00.62.50.6EVAXEvaxion Biotech A/S1.977 of 5 stars3.55.00.00.00.01.70.0PTNPalatin TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ASCNIScinai Immunotherapeutics0.2919 of 5 stars0.03.00.00.00.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIORBiora Therapeutics 3.00Buy$23.0016,937.04% UpsideEVAXEvaxion Biotech A/S 3.00Buy$10.00323.73% UpsidePTNPalatin Technologies 0.00N/AN/AN/ASCNIScinai Immunotherapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BIOR, SCNI, PTN, and EVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIORBiora Therapeutics$892K0.68N/AN/A($36.43) per share0.00EVAXEvaxion Biotech A/S$3.34M0.99N/AN/A($5.83) per share-0.40PTNPalatin Technologies$350K6.99N/AN/AN/A∞SCNIScinai Immunotherapeutics$658K4.29N/AN/A($9.84) per share-0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIORBiora Therapeutics-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%5/27/2025 (Estimated)EVAXEvaxion Biotech A/S-$22.12M-$0.72N/AN/AN/A-347.83%N/A-79.40%5/27/2025 (Estimated)PTNPalatin TechnologiesN/A-$1.55N/A∞N/AN/AN/AN/AN/ASCNIScinai Immunotherapeutics-$6.50M-$9.57N/A∞N/AN/AN/A-30.48%7/1/2025 (Estimated)Latest BIOR, SCNI, PTN, and EVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025EVAXEvaxion Biotech A/S-$0.65N/AN/AN/A$0.06 millionN/A5/7/2025Q4 2024SCNIScinai ImmunotherapeuticsN/A-$10.40N/A-$10.40N/A$0.21 million4/1/2025Q4 2024EVAXEvaxion Biotech A/S-$0.26-$0.07+$0.19-$0.07$1.66 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIORBiora TherapeuticsN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIORBiora TherapeuticsN/A0.050.05EVAXEvaxion Biotech A/S7.991.002.80PTNPalatin TechnologiesN/AN/AN/ASCNIScinai Immunotherapeutics0.061.161.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIORBiora Therapeutics43.74%EVAXEvaxion Biotech A/S11.04%PTNPalatin Technologies11.50%SCNIScinai Immunotherapeutics58.41%Insider OwnershipCompanyInsider OwnershipBIORBiora Therapeutics51.08%EVAXEvaxion Biotech A/S41.64%PTNPalatin Technologies7.10%SCNIScinai Immunotherapeutics60.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIORBiora Therapeutics1204.52 million2.21 millionOptionableEVAXEvaxion Biotech A/S601.40 million685,000No DataPTNPalatin Technologies3026.01 millionN/AN/ASCNIScinai Immunotherapeutics201.00 million334,000Not OptionableBIOR, SCNI, PTN, and EVAX HeadlinesRecent News About These CompaniesFinancial Survey: Scinai Immunotherapeutics (NASDAQ:SCNI) and Ocugen (NASDAQ:OCGN)May 23, 2025 | americanbankingnews.comScinai Announces Annual Financial Results for 2024May 7, 2025 | prnewswire.comScinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin DiseasesMay 1, 2025 | prnewswire.comScinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological ConditionsMarch 27, 2025 | prnewswire.comScinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025March 17, 2025 | prnewswire.comSCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENTMarch 5, 2025 | prnewswire.comScinai Immunotherapeutics Ltd. (SCNI)January 28, 2025 | ca.finance.yahoo.comScinai Immunotherapeutics (NASDAQ: SCNI) to Engage Investors at January ConferencesJanuary 7, 2025 | theglobeandmail.comScinai to Connect with Investors and Pharma Leaders at Upcoming Key US ConferencesJanuary 6, 2025 | prnewswire.comScinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.December 16, 2024 | prnewswire.comProf. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory BoardDecember 5, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory BoardDecember 3, 2024 | theglobeandmail.comThere Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of ProfitabilityNovember 29, 2024 | uk.finance.yahoo.comDr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory BoardNovember 27, 2024 | prnewswire.comScinai Immunotherapeutics Reports Financial Turnaround and GrowthNovember 26, 2024 | markets.businessinsider.comScinai Immunotherapeutics Gains Shareholder ConfidenceNovember 23, 2024 | markets.businessinsider.comScinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 millionNovember 22, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ: SCNI) to Spotlight I&I Pipeline, CDMO Services at BIO-Europe 2024October 31, 2024 | theglobeandmail.comScinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024October 31, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ:SCNI) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comMedia Sentiment Over TimeBIOR, SCNI, PTN, and EVAX Company DescriptionsBiora Therapeutics NASDAQ:BIOR$0.14 0.00 (-0.37%) As of 05/23/2025Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Evaxion Biotech A/S NASDAQ:EVAX$2.36 +0.48 (+25.53%) Closing price 04:00 PM EasternExtended Trading$2.28 -0.07 (-3.18%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Palatin Technologies NYSE:PTN$0.09 -0.08 (-44.65%) As of 05/7/2025Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.Scinai Immunotherapeutics NASDAQ:SCNI$2.82 +0.06 (+2.32%) Closing price 03:58 PM EasternExtended Trading$2.82 -0.01 (-0.32%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
